Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on ...

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

Rapid Activity of Platelet Inhibitor Drugs Study 2

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2013-03-06

Last Posted Date: 2014-09-25

Lead Sponsor: David Antoniucci

Target Recruit Count: 50

Registration Number: NCT01805570

Locations: 🇮🇹
Careggi Hospital, Florence, Italy

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Prasugrel

First Posted Date: 2013-02-18

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 341

Registration Number: NCT01794000

Locations: 🇺🇸
Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Oakland, Oakland, California, United States
🇺🇸
Stanford Univ Medical Center, Palo Alto, California, United States

and more 18 locations

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-02-12

Last Posted Date: 2017-04-04

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 24

Registration Number: NCT01789814

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome

Phase 3

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-01-29

Last Posted Date: 2013-01-29

Lead Sponsor: Gennaro Sardella

Target Recruit Count: 68

Registration Number: NCT01778842

Locations: 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

The Elderly ACS II Trial

Phase 4

Conditions: Acute Coronary Syndrome
Coronary Arteriosclerosis
Myocardial Ischemia
Cardiovascular Diseases

Interventions: Drug: prasugrel
Drug: Clopidogrel

First Posted Date: 2013-01-29

Last Posted Date: 2016-10-21

Lead Sponsor: Arcispedale Santa Maria Nuova-IRCCS

Target Recruit Count: 2000

Registration Number: NCT01777503

Locations: 🇮🇹
Azienda Ospedaliera "Ospedale Civile di Legnano", Legnano, MI, Italy
🇮🇹
Arcispedale Santa Maria Nuova- IRCCS, Reggio Emilia, Italy

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome
Unstable Angina

Interventions: Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2013-01-24

Last Posted Date: 2015-06-11

Lead Sponsor: University of Cologne

Target Recruit Count: 49

Registration Number: NCT01774838

Locations: 🇩🇪
Cardiology, University Hospital of Cologne, Cologne, Germany

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Procedure: Coronary stenting
Drug: Ticagrelor
Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2012-10-04

Last Posted Date: 2016-09-07

Lead Sponsor: Johannes Gutenberg University Mainz

Target Recruit Count: 126

Registration Number: NCT01700322

Locations: 🇩🇪
2 Medical Clinic, Mainz, Germany

Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2012-07-17

Last Posted Date: 2013-01-23

Lead Sponsor: University of Patras

Target Recruit Count: 56

Registration Number: NCT01642966

Locations: 🇬🇷
Cardiology Department Patras University Hospital, Patras, Achaia, Greece

Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study

Phase 4

Completed

Conditions: Coronary Artery Disease
Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2012-07-17

Last Posted Date: 2013-01-23

Lead Sponsor: University of Patras

Target Recruit Count: 30

Registration Number: NCT01642940

Locations: 🇬🇷
Cardiology Department Patras University Hospital, Patras, Achaia, Greece

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

Phase 3

Completed

Conditions: Acute Coronary Syndromes

Interventions: Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2012-07-16

Last Posted Date: 2019-02-11

Lead Sponsor: Dong-A University

Target Recruit Count: 70

Registration Number: NCT01641510

Locations: 🇰🇷
DongA University Hospital, Busan, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy